GlassScriptPhysician profile
Grace Escamilla
NPI 1235525023
$1,297.03
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $44.51 · 2021: $271 · 2022: $120 · 2023: $172 · 2024: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $222.18 | 2019-2022 | |
| Novo Nordisk INC | $197.13 | 2019-2024 | Wegovy |
| Welch Allyn | $191.60 | 2021 | |
| Pfizer INC. | $111.90 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $83.61 | 2019-2022 | |
| Lilly USA, LLC | $63.45 | 2019-2023 | Trulicity, Mounjaro |
| Novartis Pharmaceuticals Corporation | $62.41 | 2022-2024 | |
| Glaxosmithkline, LLC. | $61.21 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $43.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.00 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $29.92 | 2019-2020 | |
| Dynavax Technologies Corporation | $28.60 | 2019-2023 | Heplisav-B |
| Clarus Therapeutics INC. | $19.84 | 2021 | |
| Nevro Corp. | $19.03 | 2021 | |
| Eisai INC. | $18.08 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2024 | Jardiance |
| Shire North American Group INC | $16.60 | 2019 | |
| Pacira Therapeutics, INC. | $15.22 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.94 | 2019 | |
| Insmed, INC. | $14.48 | 2019 | |
| Insulet Corporation | $13.71 | 2019 | |
| Amgen INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Escamilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.